Skip Navigation



Annals of Oncology Advance Access published online on March 29, 2007
Annals of Oncology, doi:10.1093/annonc/mdm012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/5/931    most recent
mdm012v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Veelken, H
Right arrow Articles by Schmitt-Graeff, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veelken, H
Right arrow Articles by Schmitt-Graeff, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy

H Veelken1,*, S Vik Dannheim1, J Schulte Moenting2, UM Martens1, J Finke1 and A Schmitt-Graeff3

1 Departments of Internal Medicine I (Hematology/Oncology)
2 Department of Biometry and Statistics
3 Department of Pathology, Freiburg University Medical Center, Freiburg, Germany

* Correspondence to: Dr H. Veelken, Department of Hematology/Oncology, University Medical Center, Hugstetter Strasse 55, D-79106 Freiburg, Germany. Tel: +49-761-270-7175; Fax: +49-761-270-7177; E-mail: hendrik.veelken{at}uniklinik-freiburg.de

Background: For patients with diffuse large B-cell lymphoma (DLBCL), the International Prognostic Index (IPI) predicts the likelihood for cure with chemotherapy. Biological parameters, including expression of Bcl-6, Bcl-2, CD10, major histocompatibility complex class II, and categorization as germinal center (GC) type have been described as IPI-independent prognostic factors.

Patients and methods: Biological parameters were evaluated retrospectively by immunohistochemistry in 60 consecutive DLBCL patients of the prerituximab era. Forty-one of 60 patients underwent a risk-adapted treatment strategy including autologous stem-cell transplantation for high-risk patients (age-adjusted IPI = 2–3; slow response to chemotherapy).

Results: Bcl-6 expression was associated with superior overall survival (OS) independently of the IPI. Inferior progression-free survival (PFS) was independently correlated with high expression of Bcl-2 and low positivity for HLA-DR and CD10. Distinction into GC and non-GC DLBCL on the basis of Bcl-6, CD10, and IRF-4 expression had no independent prognostic value. Within the risk-adapted treatment strategy, only HLA-DR retained a prognostic impact on OS (P = 0.0058) and PFS (P = 0.0002).

Conclusions: In 60 patients with DLBCL treated with risk-adapted therapy, immunohistochemical subcategorization of DLBCL into GC and non-GC type has little clinical value. The IPI-associated risk appears to be mitigated by intensified upfront therapy. Low HLA-DR expression is associated with poor outcome after intensified upfront therapy. Therefore, additional treatment modalities appear to be required.

Bcl-6 protein, diffuse large-cell lymphoma, hematopoietic stem-cell transplantation, HLA-DR antigens, immunohistochemistry

Received for publication August 24, 2006. Revision received December 19, 2006. Accepted for publication January 11, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
H.-W. Bernd, M. Ziepert, C. Thorns, W. Klapper, H.-H. Wacker, M. Hummel, H. Stein, M.-L. Hansmann, G. Ott, A. Rosenwald, et al.
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials
Haematologica, November 1, 2009; 94(11): 1569 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Chadburn, A. Chiu, J. Y. Lee, X. Chen, E. Hyjek, A. H. Banham, A. Noy, L. D. Kaplan, J. A. Sparano, K. Bhatia, et al.
Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients From AIDS Malignancies Consortium Clinical Trials 010 and 034
J. Clin. Oncol., October 20, 2009; 27(30): 5039 - 5048.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. W.L. Choi, D. D. Weisenburger, T. C. Greiner, M. A. Piris, A. H. Banham, J. Delabie, R. M. Braziel, H. Geng, J. Iqbal, G. Lenz, et al.
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
Clin. Cancer Res., September 1, 2009; 15(17): 5494 - 5502.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. M. Rimsza, M. L. LeBlanc, J. M. Unger, T. P. Miller, T. M. Grogan, D. O. Persky, R. R. Martel, C. M. Sabalos, B. Seligmann, R. M. Braziel, et al.
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
Blood, October 15, 2008; 112(8): 3425 - 3433.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al.
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol., October 1, 2008; 26(28): 4587 - 4594.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.